Rapport Therapeutics (RAPP) Reiterated at Market Outperform by Citizens on RAP-219 Data
Tweet Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $80.00 price target on Rapport Therapeutics (NASDAQ: RAPP).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
